2月24日 - ** 制药商Axsome TherapeuticsAXSM.O股价盘前上涨1.6%至139.98美元
** AXSM称， (link)，其药物Symbravo在一项治疗偏头痛的后期试验中达到了主要目标。
** Symbravo是美洛昔康和利扎曲普坦两种药物的复方制剂
** 在试验中，Symbravo在缓解偏头痛方面比口服CGRP抑制剂更有效，47.9%的患者在2小时内无痛 ， 而 口服CGRP抑制剂的患者只有1%无痛 。
** 不建议有心脏病、高血压或肾病的患者、孕妇或哺乳期妇女使用 Symbravo
** 2024 年，AXSM 的销售额增长 6.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.